High Growth Tech Stocks In The US Market November 2025

In the midst of a volatile U.S. market, where concerns about AI valuations have led to fluctuations in major indices like the Dow Jones and Nasdaq, investors are closely watching earnings reports and economic indicators amid a historic government shutdown. As tech stocks face renewed scrutiny, identifying high-growth opportunities requires careful consideration of companies' adaptability to current trends and their potential for innovation in an uncertain economic landscape.

Top 10 High Growth Tech Companies In The United States

Click here to see the full list of 79 stocks from our US High Growth Tech and AI Stocks screener.

Below we spotlight a couple of our favorites from our exclusive screener.

Compass Therapeutics (CMPX)

Simply Wall St Growth Rating: ★★★★★☆

Overview: Compass Therapeutics, Inc. is a clinical-stage biopharmaceutical company specializing in the development of antibody-based therapeutics for treating various human diseases, with a market capitalization of $650.26 million.

Operations: Compass Therapeutics focuses on developing antibody-based therapeutics primarily for oncology applications in the United States. The company operates as a clinical-stage biopharmaceutical entity, with its business model centered around research and development activities aimed at advancing innovative treatments.

Compass Therapeutics, despite its challenging financials with a net loss widening to $50.77 million from $34.34 million year-over-year as of September 2025, shows potential in the high-growth biotech sector. The firm's inclusion in the S&P Biotechnology Select Industry Index underscores its relevance in an industry driven by innovation and R&D intensity. Notably, Compass is navigating through significant R&D phases, evident from its active participation in multiple high-profile healthcare conferences, signaling ongoing endeavors to overturn unprofitability through strategic advancements and potentially lucrative drug developments. This strategy could be pivotal as it aims for profitability within three years amidst a volatile share price landscape.

• Take a closer look at Compass Therapeutics' potential here in our health report.

• Explore historical data to track Compass Therapeutics' performance over time in our Past section.

Stoke Therapeutics (STOK)

Simply Wall St Growth Rating: ★★★★★☆

Overview: Stoke Therapeutics, Inc. is an early-stage biopharmaceutical company focused on developing treatments for severe genetic diseases through the upregulation of protein expression, with a market cap of $1.39 billion.

Operations: Stoke Therapeutics focuses on developing therapies for severe genetic diseases by enhancing protein expression. As an early-stage biopharmaceutical company, it does not currently generate revenue from product sales.

Stoke Therapeutics, despite its recent net loss of $38.35 million for Q3 2025, shows promise with a substantial increase in sales to $183.02 million over nine months, reflecting a strong revenue growth rate of 20.1% annually. This performance is complemented by an impressive forecast of earnings growth at 41.6% per year, signaling potential recovery and profitability ahead. The company's strategic focus on R&D is evident from its participation in the FALCON study and development of STK-002 for treating optic atrophy, underscoring its commitment to addressing unmet medical needs through innovative therapies.

• Navigate through the intricacies of Stoke Therapeutics with our comprehensive health report here.

• Review our historical performance report to gain insights into Stoke Therapeutics''s past performance.

Vishay Precision Group (VPG)

Simply Wall St Growth Rating: ★★★★☆☆

Overview: Vishay Precision Group, Inc. operates in the precision measurement and sensing technologies sector across the United States, Europe, Israel, Asia, and Canada with a market cap of $473.93 million.

Operations: Vishay Precision Group specializes in precision measurement and sensing technologies, generating revenue through its diverse geographic operations. The company's cost structure and financial performance details are not specified in the provided data.

Vishay Precision Group, with its modest annual revenue growth of 5.3%, contrasts sharply against a backdrop of high-growth tech sectors, yet it's the company's earnings forecast that intrigues, projecting a robust increase of 33.7% annually. This growth is underpinned by strategic executive appointments aiming to enhance product strategy and operations efficiency, signaling a potential shift towards more dynamic market positioning. Moreover, recent financials reveal an encouraging turnaround from a net loss to a net income of $7.86 million in Q3 2025, alongside consistent R&D investment that could further solidify its competitive edge in precision technology.

• Delve into the full analysis health report here for a deeper understanding of Vishay Precision Group.

• Examine Vishay Precision Group's past performance report to understand how it has performed in the past.

Turning Ideas Into Actions

• Unlock more gems! Our US High Growth Tech and AI Stocks screener has unearthed 76 more companies for you to explore.Click here to unveil our expertly curated list of 79 US High Growth Tech and AI Stocks.
• Hold shares in these firms? Setup your portfolio in Simply Wall St to seamlessly track your investments and receive personalized updates on your portfolio's performance.
• Unlock the power of informed investing with Simply Wall St, your free guide to navigating stock markets worldwide.

Ready For A Different Approach?

• Explore high-performing small cap companies that haven't yet garnered significant analyst attention.
• Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management.
• Find companies with promising cash flow potential yet trading below their fair value.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com